诺华在肿瘤免疫战场加速布局，通过并购在美国的生物公司，进入PD-1分子靶向治疗的疯狂竞赛。诺华2月17日宣布，收购位于Cambridge, MA 的Costim制药公司。诺华一如既往没有在公告中披露交易条款和金额，只提及潜在目标PD-1抗体——或许是现在最热门的癌症靶标。
Novartis expands cancer immunotherapy research program with acquisition of CoStim
Novartis expands cancer immunotherapy research program with acquisition of CoStim
Acquisition adds novel immune modulating targets and technology to accelerate Novartis cancer immunotherapy program
Novartis and University of Pennsylvania CAR immunotherapy research combined with CoStim targets and technology strengthens Novartis' position in cancer immunotherapy discovery
Basel, February 17, 2014 - Novartis announced today that it is broadening its cancer immunotherapy research program with the acquisition of CoStim Pharmaceuticals Inc., a Cambridge, MA-based, privately held biotechnology company focused on harnessing the immune system to eliminate immune-blocking signals from cancer.
Increasing evidence points to the role of the immune system in controlling cancer and to opportunities for creating effective oncology therapies for cancer patients by stimulating a targeted immune response. Already leading in cancer immunotherapy, with investigative chimeric antigen receptor (CAR) technology being developed in collaboration with the University of Pennsylvania, with this acquisition Novartis is adding late discovery stage immunotherapy programs directed to several targets, including PD-1. These medicines could benefit patients by circumventing cancer's ability to develop resistance against current single drugs.
"Therapy for many types of cancers are expected to increasingly rely upon rational combinations of agents," said Dr. Mark Fishman, President of the Novartis Institutes for BioMedical Research. "Immunotherapy agents provide additional arrows in our quiver for such combinations. They complement our extensive portfolio of drugs that hit genetically-defined cancer-causing pathways, and also may be relevant to expansion of CAR therapies."